查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1837124

移植診斷市場（按診斷應用、技術、器官類型和最終用戶分類）—2025-2032 年全球預測

Transplant Diagnostics Market by Diagnostic Application, Technology, Organ Type, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，移植診斷市場規模將成長至 90.1 億美元，複合年成長率為 7.88%。

主要市場統計數據
基準年2024年 49.1億美元
預計2025年 52.9億美元
預測年份：2032年 90.1億美元
複合年成長率（%） 7.88%

全面介紹移植診斷，描述分子創新、臨床工作流程和指導護理途徑的監管要求的融合

移植診斷處於免疫學、分子生物學和臨床工作流程最佳化的關鍵交叉點，快速可靠的診斷是患者預後和計畫永續性的基礎。分子檢測、次世代定序和數位PCR的最新進展擴展了臨床醫生和實驗室主任可用的診斷套件，從而能夠更準確地進行供體-受體匹配、更早地發現移植物損傷以及進行更精細的病原體監測。這些技術進步與營運趨勢相輔相成，這些趨勢強調更快的周轉速度、自動化數據整合以及可擴展的實驗室模型，這些模型可以在不犧牲分析嚴謹性的情況下支援高通量檢測。

因此，從移植中心到診斷實驗室的相關人員正在重新調整臨床路徑和採購流程，以在控制成本和複雜性的同時，充分挖掘先進診斷技術的臨床價值。同時，監管機構對檢測驗證、資料完整性和互通性的關注度日益提高，這推動了對標準化工作流程和證據產生的需求。因此，領導者必須權衡新型檢測方法的臨床效益與營運現實，並協調臨床、實驗室和行政部門的相關人員，確保診斷創新轉化為移植器官存活率和病人安全的可衡量改善。

新的分子平台、數位整合和協作證據產生如何重塑移植診斷的臨床實踐和採用途徑

隨著新技術、以數據為中心的護理模式以及不斷發展的臨床方案的融合，移植診斷的模式正在發生變化，從而重新定義標準實踐。首先，分子診斷正在從單一分析物檢測轉向多重和基於序列的方法，從而提供更豐富的免疫遺傳學和病原體譜。這種轉變正在改變移植團隊處理捐贈者選擇、免疫抑制管理和移植後監測的方式，因為臨床醫生現在可以獲得縱向的生物標記軌跡，而不是孤立的簡介。

其次，實驗室自動化和數位化整合正在減少人工差異，縮短檢測週轉時間。因此，移植計畫正在採用更積極的監測方案，以便更早發現移植物損傷，並及時調整治療方案。第三，監管和報銷格局正在不斷發展，以解決新型診斷方法的臨床效用和證據閾值，促使製造商和醫療系統投資於真實世界證據研究和支付方參與。最後，診斷公司、臨床中心和數據平台之間的夥伴關係正在加速伴隨診斷和標準化報告框架的開發，這些合作降低了應用門檻，並為在不同醫療環境中的可擴展部署開闢了道路。

評估近期美國關稅對移植診斷採購、製造和臨床工作流程的營運和供應鏈影響

2025年，美國實施的關稅政策為依賴全球供應鏈的製造商、實驗室和臨床計畫帶來了額外的複雜性。依賴進口的組件，例如專用試劑、儀器零件和定序耗材，正面臨採購成本增加和採購計畫中斷的問題。這直接導致實驗室管理人員必須重新評估其供應商關係，多元化供應商網路，在某些情況下，還要優先考慮安全庫存，以保持檢測服務的連續性。

同時，製造商正在透過合理化其區域製造地和加快本地化進程來應對，以減少與關稅相關的波動帶來的影響。此類調整通常需要大量的資本投入和較長的前置作業時間才能實現成本效益。同時，在固定報銷制度下運作的臨床項目正面臨營業利潤率的壓力、更嚴格的檢測利用優先順序以及更嚴格的成本效益審查。為此，許多相關人員正在採用策略籌資策略，最佳化批次處理，並重組工作流程以整合臨床適用的檢測。從中期來看，供應鏈彈性、供應商多元化和合約靈活性可能會成為尋求維持服務連續性和管理貿易政策變化財務影響的組織必不可少的能力。

深入的細分分析揭示了診斷應用、技術模式、器官特定需求和最終用戶結構如何影響採用和投資重點

詳細了解細分市場可以提供切實可行的見解，了解臨床需求和技術採用之間的分歧所在。從診斷應用的角度來看，供體-受體匹配、移植物監測、 HLA型檢測和傳染病篩檢各自佔據不同的臨床路徑，具有不同的分析優先順序。 HLAHLA型檢測代表雙重解析度需求：高解析度檢測能夠對複雜病例進行準確的等位基因水平匹配，而低解析度方法仍能滿足常規相容性篩檢。傳染病篩檢涵蓋細菌、真菌和病毒領域，病毒監測本身需要針對巨細胞病毒、EB病毒、肝炎病毒和 HIV 等病原體進行有針對性的檢測，每種病毒都對實驗室施加了特定的靈敏度和周轉限制。

酵素測定和流式細胞技術在許多診斷工作流程中起著基礎性的作用，而 PCR 方法（包括定量 PCR 和數位 PCR）則可提供高度靈敏的定量分析，可用於病毒量監測和微小殘留疾病檢測。新一代定序和桑格定序技術擴大應用於表徵 HLA 等位基因和對複雜病原體基因型鑒定，從而產生支持個性化免疫抑制策略的高解析度數據。器官類型細分揭示了心臟、腎臟、肝臟、肺部和胰臟移植的不同臨床需求，揭示了因移植物特異性生物標記、監測頻率和風險接受度而異的檢測模式。最後，最終用戶細分揭示了診斷實驗室、醫院、研究機構和移植中心的運作觀點。在醫院內部，私立和公立機構之間的差異會影響採購模式、預算限制和實施時間表。結合這些相交的部分，可以揭示在檢測開發、實驗室自動化和臨床檢驗方面的投資在哪些方面可以產生最大的臨床和營運影響。

區域資訊詳細說明了臨床能力、監管多樣性和供應鏈動態如何推動全球醫療保健市場的差異化採用模式

區域動態對於理解臨床實踐、法律規範和報銷政策如何影響移植護理中的診斷採用至關重要。在美洲，臨床網路和集中實驗室通常優先考慮快速分子檢測和精簡的供應管道，主要移植中心成為影響國家實踐的早期採用者和參考中心。在歐洲、中東和非洲，法規環境、報銷系統和實驗室基礎設施的多樣性導致了不同的採用率，一些先進的實踐與資源受限的環境共存，後者優先考慮具有成本效益的穩健測試。在亞太地區，實驗室能力的快速投資，加上臨床數量的增加和對國內製造業的重視，加速了定序和基於 PCR 的診斷方法的採用，特別是在都市區三級醫療中心。

在這些全部區域，互通性、統一的標準和跨境資料共用對於多中心合作研究和縱向監測計畫仍然至關重要。因此，區域策略必須將全球最佳實踐與當地監管現狀和供應鏈考量相協調，並實現可擴展的實施，同時尊重臨床工作流程和付款人系統的差異。策略性區域夥伴關係和以本地為重點的檢驗研究是彌合能力差距並將創新診斷方法引入不同醫療生態系統常規實踐的有效機制。

競爭格局分析強調了專業創新者、平台提供者和資訊解決方案之間的相互作用，這將決定市場領導地位和臨床應用

移植診斷領域的競爭態勢反映了專業創新企業與大型平台供應商之間的平衡，後者提供涵蓋檢測、設備和資訊學的一體化解決方案。利基市場公司通常引領檢測創新，提供高解析度HLA型檢測、標靶病毒監測面板以及針對特定未滿足臨床需求的新型生物標記方法。相較之下，大型公司則利用其規模優勢投資實驗室自動化、全球分銷網路和監管項目，以推動更廣泛的市場滲透。檢測開發商、設備製造商和臨床網路之間的夥伴關係和策略聯盟日益普遍，這為檢驗臨床效用並透過現有管道加速應用提供了途徑。

同時，能夠實現標準化彙報、縱向資料視覺化以及與電子健康記錄整合的軟體和資訊學公司正成為關鍵的競爭優勢。這些功能透過將原始檢測結果轉化為移植臨床醫生可操作的見解，從而增強了臨床效用。隨著競爭加劇，圍繞專有檢測方法的知識產權、與現有檢測生態系統整合的便捷性以及展示真實世界臨床結果的能力將決定哪些公司能夠成功獲得移植中心和參考實驗室的青睞。

為診斷開發人員、實驗室和臨床領導者提供可行的建議，以使證據產生、互通性和彈性供應策略與採用目標保持一致

行業領導者必須優先考慮證據生成、互通性和供應鏈彈性，以將技術前景轉化為常規臨床實踐。首先，新診斷產品的申辦者必須投資於嚴格的臨床檢驗研究和真實世界證據項目，以證明其在代表性移植族群和醫療環境中的臨床效用。這種方法將增強臨床醫生的信心和付款人的參與度，同時提供適當的使用指南。其次，供應商和實驗室必須透過採用標準化報告格式、電子健康記錄API和實驗室資訊系統整合來設計互通性。

第三，建立靈活的供應鏈，涵蓋多家合格供應商、區域性生產應急計畫以及庫存管理策略，可以降低外部政策和物流中斷帶來的營運風險。第四，商業策略應強調與醫院和付款人進行基於價值觀的對話，並根據臨床結果、工作流程效率和總護理成本來製定診斷方案。最後，與移植中心和研究機構進行合作試點，為實證應用開闢道路，並提供可操作的回饋循環，以改善產品設計和服務模式。

一種透明而嚴謹的調查方法，結合臨床文獻、監管指導和該領域從業人員的見解來支持基於證據的結論

本執行摘要所依據的研究整合了同行評審文獻、監管指南、官方臨床指南和最新的行業揭露，以確保觀點的平衡性和實證性。一級資訊來源包括臨床檢驗研究、檢測性能報告以及說明檢測方法和分析特性的技術白皮書。我們審查了監管文件和指導聲明，以了解對驗證、報告和實驗室品質保證不斷變化的期望。此外，實驗室主任、移植臨床醫生和供應鏈經理的定性意見為實施、週轉和採購提供了切實可行的考慮。

為確保分析的嚴謹性，我們將技術論點與獨立評估進行交叉引用，並優先考慮多中心研究和成熟臨床計畫的數據。在討論實務意義時，我們運用個案和實務經驗來闡明常見的障礙和緩解措施。本報告著重調查方法透明度，附錄詳細說明了納入標準、來源層級和研究局限性，以支持同儕複製和嚴格評估。

總結性結論強調了技術成熟度、營運彈性和協作證據產生將如何決定移植診斷的臨床影響和採用軌跡

先進分子技術、實驗室自動化以及日益成長的臨床期望的整合，使移植診斷成為改善移植結果和患者安全的關鍵工具。從供體選擇和HLA型檢測到感染疾病監測和移植物監測，高解析度檢測方法和整合資料工作流程在臨床路徑中的應用正在重塑醫療決策。同時，貿易政策變化和區域能力差距等外部壓力凸顯了對彈性供應鏈、本地化檢驗和靈活實施策略的需求。

展望未來，那些將嚴謹的證據生成、可互通的系統設計和策略性商業性合作相結合的相關人員，將最有能力將診斷創新轉化為可衡量的臨床價值。檢測開發人員、臨床中心和資訊學提供者之間的跨部門合作將加速這一轉變，使診斷從一次性檢測轉變為持續的、數據驅動的監測，從而主動管理患者並改善長期療效。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 結合液態生物檢體與遊離DNA檢測來檢測早期器官排斥
  • 引入人工智慧驅動的影像分析，用於移植診斷中的準確組織病理學評估
  • 引入多重免疫檢測，同時監測供體特異性抗體和免疫標記
  • 擴展照護現場檢測平台，實現移植相關感染疾病的快速檢測
  • 開發非侵入性尿液生物標記組以預測功能衰退前的慢性移植物功能障礙
  • 影響移植基因表現表現譜檢測市場進入的監管核准和報銷挑戰

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 移植診斷市場（依診斷應用）

  • 捐贈者和接受者匹配
  • 移植物監測
  • HLA型檢測
    • 高解析度
    • 低解析度
  • 傳染病篩檢
    • 細菌篩檢
    • 真菌檢測
    • 病毒篩檢
      • 巨細胞病毒
      • EB病毒
      • 肝炎病毒
      • HIV

9. 移植診斷市場（依技術）

  • 酵素測定
  • 流式細胞技術
  • PCR
    • 數位PCR
    • QPCR
  • 定序
    • 新一代
    • 桑格定序

第 10 章。按器官類型分類的移植診斷市場

  • 心
  • 腎
  • 肝
  • 肺
  • 胰臟

第 11 章 移植診斷市場（依最終使用者）

  • 診斷實驗室
  • 醫院
    • 私立醫院
    • 公立醫院
  • 研究所
  • 移植中心

第12章 移植診斷市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 移植診斷市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國移植診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • F. Hoffmann-La Roche Ltd
    • Thermo Fisher Scientific Inc.
    • Abbott Laboratories
    • Danaher Corporation
    • Illumina, Inc.
    • Qiagen NV
    • Bio-Rad Laboratories, Inc.
    • DiaSorin SpA
    • CareDx, Inc.
    • Natera, Inc.
Product Code: MRR-031685195790

The Transplant Diagnostics Market is projected to grow by USD 9.01 billion at a CAGR of 7.88% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.91 billion
Estimated Year [2025] USD 5.29 billion
Forecast Year [2032] USD 9.01 billion
CAGR (%) 7.88%

A comprehensive introduction to transplant diagnostics that explains the convergence of molecular innovation, clinical workflows, and regulatory imperatives guiding care pathways

Transplant diagnostics occupies a pivotal intersection of immunology, molecular biology, and clinical workflow optimization, where rapid and reliable diagnostics underpin patient outcomes and program sustainability. Recent advances in molecular assays, next-generation sequencing, and digital PCR have expanded the diagnostic toolkit available to clinicians and laboratory directors, enabling more precise donor-recipient matching, earlier detection of graft injury, and refined pathogen surveillance. These technological improvements are complemented by operational trends that emphasize faster turnaround, automated data integration, and scalable laboratory models that can support high-throughput testing without sacrificing analytical rigor.

Consequently, stakeholders from transplant centers to diagnostic laboratories are recalibrating clinical pathways and procurement processes to capture the clinical value of advanced diagnostics while managing cost and complexity. In parallel, regulatory attention on assay validation, data integrity, and interoperability is intensifying, which drives a greater need for standardized workflows and evidence generation. As a result, leaders must weigh the clinical benefits of novel assays against implementation realities, aligning stakeholders across clinical, laboratory, and administrative functions to ensure that diagnostic innovations translate into measurable improvements in graft survival and patient safety.

How emerging molecular platforms, digital integration, and collaborative evidence generation are reshaping clinical practice and adoption pathways in transplant diagnostics

The landscape of transplant diagnostics is shifting as emerging technologies, data-centric care models, and evolving clinical protocols converge to redefine standard practice. First, molecular diagnostics are moving from single-analyte tests toward multiplexed and sequencing-based approaches that deliver richer immunogenetic and pathogen profiles. This transition is changing how transplant teams approach donor selection, immunosuppression management, and post-transplant surveillance, because clinicians now have access to longitudinal biomarker trajectories rather than isolated snapshots.

Second, laboratory automation and digital integration are reducing manual variability and shortening test turnaround times, which supports more dynamic clinical decision-making. As a result, transplant programs are able to adopt more proactive monitoring regimens that detect graft injury earlier and enable timely therapeutic adjustments. Third, the regulatory and reimbursement environment is evolving to address clinical utility and evidence thresholds for novel diagnostics, prompting manufacturers and health systems to invest in real-world evidence studies and payer engagement. Finally, partnerships between diagnostics firms, clinical centers, and data platforms are accelerating the development of companion diagnostics and standardized reporting frameworks, which together lower barriers to adoption and create pathways for scalable implementation across diverse healthcare settings.

Evaluating the operational and supply chain repercussions of recent United States tariff measures on transplant diagnostics procurement, manufacturing, and clinical workflows

In 2025, tariff policies introduced in the United States have introduced an additional layer of complexity for manufacturers, laboratories, and clinical programs that rely on global supply chains. Import-dependent components, including specialized reagents, instrumentation parts, and sequencing consumables, face increased procurement costs and disrupted sourcing timelines. As an immediate consequence, laboratory managers have had to reassess vendor relationships, diversify supplier networks, and in some cases prioritize inventory safety stock to preserve continuity of testing services.

At the same time, manufacturers are responding by rationalizing regional manufacturing footprints and accelerating localization efforts to mitigate exposure to tariff-related volatility. These adjustments often require substantial capital investment and longer lead times to realize cost benefits. Meanwhile, clinical programs that operate under fixed reimbursement regimes feel pressure on operating margins, prompting tighter prioritization of test utilization and greater scrutiny over cost-effectiveness. In response, many stakeholders are adopting strategic sourcing strategies and reengineering workflows to optimize batch processing and consolidate testing where clinically appropriate. Over the medium term, supply chain resilience, supplier diversification, and contractual flexibility will become essential capabilities for organizations seeking to maintain service continuity and manage the financial impacts of trade policy shifts.

Insightful segmentation analysis revealing how diagnostic application, technological modality, organ-specific needs, and end-user structures shape adoption and investment priorities

A granular understanding of market segments provides actionable insight into where clinical demand and technology adoption are diverging. When viewed through diagnostic application lenses, donor and recipient matching, graft monitoring, HLA typing, and infectious disease screening occupy distinct clinical pathways with different analytical priorities. HLA typing presents a duality of resolution needs where high-resolution assays enable precise allele-level matching for complex cases while low-resolution approaches continue to satisfy routine compatibility screening. Infectious disease screening spans bacterial, fungal, and viral domains, with viral surveillance itself requiring targeted assays for pathogens such as cytomegalovirus, Epstein-Barr virus, hepatitis viruses, and HIV, each of which imposes specific sensitivity and turnaround constraints on laboratories.

Technology segmentation further clarifies adoption trajectories: enzymatic assays and flow cytometry maintain foundational roles in many diagnostic workflows, while PCR modalities, including quantitative PCR and digital PCR, deliver high-sensitivity quantitation useful for viral load monitoring and minimal residual disease detection. Sequencing technologies, both next-generation and Sanger, are increasingly applied for HLA allele characterization and complex pathogen genotyping, yielding higher-resolution data that supports personalized immunosuppression strategies. Organ-type segmentation highlights differentiated clinical requirements across heart, kidney, liver, lung, and pancreas transplantation, where graft-specific biomarkers, monitoring frequency, and risk tolerances drive distinct testing patterns. Finally, end-user segmentation reveals the operational perspectives of diagnostic laboratories, hospitals, research institutes, and transplant centers; within hospitals, the distinction between private and public institutions affects procurement models, budgetary constraints, and adoption timelines. Together, these intersecting segmentations elucidate where investments in assay development, laboratory automation, and clinical validation will produce the greatest clinical and operational impact.

Regional intelligence detailing how clinical capacity, regulatory diversity, and supply chain dynamics drive differentiated adoption patterns across global healthcare markets

Regional dynamics are critical to understanding how clinical practice, regulatory frameworks, and reimbursement policies influence diagnostic adoption in transplant care. In the Americas, clinical networks and centralized laboratories often prioritize rapid molecular assays and streamlined supply channels, with major transplant centers serving as early adopters and reference hubs that influence national practices. In Europe, Middle East & Africa, heterogeneity in regulatory environments, reimbursement mechanisms, and laboratory infrastructure produces a wide spectrum of adoption rates, where pockets of advanced practice coexist with resource-constrained settings that emphasize cost-effective, robust assays. In the Asia-Pacific region, rapid investments in laboratory capacity, combined with growing clinical volumes and a focus on domestic manufacturing, are driving accelerated uptake of sequencing and PCR-based diagnostics, especially in urban tertiary centers.

Across these regions, interoperability, harmonized standards, and cross-border data sharing remain pivotal for multicenter studies and longitudinal surveillance programs. Consequently, regional strategies must reconcile global best practices with local regulatory realities and supply chain considerations, enabling scalable implementations that respect differences in clinical workflows and payer systems. Strategic regional partnerships and localized validation studies are effective mechanisms to bridge capability gaps and to translate innovative diagnostics into routine practice across diverse healthcare ecosystems.

Competitive landscape analysis emphasizing the interplay of specialized innovators, platform providers, and informatics solutions that determine market leadership and clinical adoption

Competitive dynamics in transplant diagnostics reflect a balance between specialized innovators and larger platform providers that offer integrated solutions spanning assays, instrumentation, and informatics. Niche firms often lead in assay innovation, delivering high-resolution HLA typing, targeted viral surveillance panels, and novel biomarker approaches that address specific unmet clinical needs. Larger entities, by contrast, leverage scale to invest in laboratory automation, global distribution networks, and regulatory programs that facilitate broader market penetration. Partnerships and strategic alliances between assay developers, instrument manufacturers, and clinical networks are increasingly common, providing a pathway to validate clinical utility and to accelerate adoption through established channels.

In parallel, software and informatics players are becoming critical competitive differentiators by enabling standardized reporting, longitudinal data visualization, and integration with electronic health records. These capabilities enhance clinical utility by converting raw assay outputs into actionable insights for transplant clinicians. As competition intensifies, intellectual property around proprietary assays, ease of integration with existing laboratory ecosystems, and the ability to demonstrate real-world clinical outcomes will determine which companies successfully capture preference among transplant centers and reference laboratories.

Actionable recommendations for diagnostics developers, laboratories, and clinical leaders to align evidence generation, interoperability, and resilient supply strategies with adoption goals

Industry leaders should prioritize evidence-generation, interoperability, and supply chain resilience to convert technological promise into routine clinical practice. First, sponsors of new diagnostics must invest in rigorous clinical validation studies and real-world evidence programs that demonstrate clinical utility across representative transplant populations and care settings. This approach accelerates clinician trust and payer engagement, while informing appropriate use guidelines. Second, vendors and laboratories should design for interoperability by adopting standardized reporting formats, APIs for electronic health records, and laboratory information system integrations that reduce implementation friction and enable scalable deployment across hospital networks.

Third, building flexible supply chains with multiple qualified suppliers, regional manufacturing contingencies, and inventory management strategies will mitigate the operational risk of external policy and logistics disruptions. Fourth, commercial strategies should emphasize value-based conversations with hospitals and payers, framing diagnostics in terms of clinical outcomes, workflow efficiency, and total cost of care. Finally, fostering collaborative pilots with transplant centers and research institutes creates an evidence-driven pathway for adoption and provides practical feedback loops that refine product design and service models.

A transparent and rigorous research methodology combining clinical literature, regulatory guidance, and frontline practitioner insights to support evidence-based conclusions

The research underpinning this executive summary synthesized peer-reviewed literature, regulatory guidance, public clinical guidelines, and recent industry disclosures to ensure a balanced, evidence-based perspective. Primary sources included clinical validation studies, assay performance reports, and technical white papers that describe assay methodologies and analytical characteristics. Regulatory documents and guidance statements were reviewed to capture evolving expectations for validation, reporting, and laboratory quality assurance. In addition, qualitative inputs from laboratory directors, transplant clinicians, and supply chain managers informed practical considerations around implementation, turnaround, and procurement.

Analytical rigor was maintained through cross-referencing technical claims against independent evaluations and by prioritizing data from multicenter studies and established clinical programs. Where real-world operational impacts were discussed, case examples and implementation lessons were used to illustrate common barriers and mitigation strategies. Methodological transparency is central to the report, and appendices detail inclusion criteria, source hierarchies, and limitations to support reproducibility and critical appraisal by technical audiences.

Concluding synthesis highlighting how technological maturation, operational resilience, and collaborative evidence generation will determine the clinical impact and adoption trajectory of transplant diagnostics

The convergence of advanced molecular technologies, enhanced laboratory automation, and heightened clinical expectations positions transplant diagnostics as a critical enabler of improved graft outcomes and patient safety. Throughout clinical pathways, from donor selection and HLA typing to infectious disease surveillance and graft monitoring, the adoption of higher-resolution assays and integrated data workflows is reshaping care decisions. At the same time, external pressures such as trade policy shifts and heterogeneous regional capabilities underscore the need for resilient supply chains, localized validation, and adaptable implementation strategies.

Moving forward, stakeholders who combine rigorous evidence generation, interoperable systems design, and strategic commercial engagement will be best positioned to translate diagnostic innovation into measurable clinical value. Cross-sector collaboration between assay developers, clinical centers, and informatics providers will accelerate this transition, enabling diagnostics to move from episodic testing toward continuous, data-driven monitoring that supports proactive patient management and improved long-term outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of liquid biopsy using cell-free DNA assays for early organ rejection detection
  • 5.2. Adoption of AI-driven image analysis for precise histopathological evaluation in transplant diagnostics
  • 5.3. Implementation of multiplex immunoassays for simultaneous monitoring of donor-specific antibodies and immune markers
  • 5.4. Expansion of point-of-care molecular testing platforms to enable rapid detection of transplant-related infections
  • 5.5. Development of noninvasive urinary biomarker panels to predict chronic allograft injury before functional decline
  • 5.6. Regulatory approval and reimbursement challenges influencing market access for gene expression profiling tests in transplantation

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Transplant Diagnostics Market, by Diagnostic Application

  • 8.1. Donor Recipient Matching
  • 8.2. Graft Monitoring
  • 8.3. Hla Typing
    • 8.3.1. High Resolution
    • 8.3.2. Low Resolution
  • 8.4. Infectious Disease Screening
    • 8.4.1. Bacterial Screening
    • 8.4.2. Fungal Screening
    • 8.4.3. Viral Screening
      • 8.4.3.1. Cytomegalovirus
      • 8.4.3.2. Epstein Barr Virus
      • 8.4.3.3. Hepatitis Viruses
      • 8.4.3.4. Hiv

9. Transplant Diagnostics Market, by Technology

  • 9.1. Enzymatic Assays
  • 9.2. Flow Cytometry
  • 9.3. Pcr
    • 9.3.1. Digital Pcr
    • 9.3.2. Qpcr
  • 9.4. Sequencing
    • 9.4.1. Next Generation
    • 9.4.2. Sanger

10. Transplant Diagnostics Market, by Organ Type

  • 10.1. Heart
  • 10.2. Kidney
  • 10.3. Liver
  • 10.4. Lung
  • 10.5. Pancreas

11. Transplant Diagnostics Market, by End User

  • 11.1. Diagnostic Laboratories
  • 11.2. Hospitals
    • 11.2.1. Private Hospitals
    • 11.2.2. Public Hospitals
  • 11.3. Research Institutes
  • 11.4. Transplant Centers

12. Transplant Diagnostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Transplant Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Transplant Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. F. Hoffmann-La Roche Ltd
    • 15.3.2. Thermo Fisher Scientific Inc.
    • 15.3.3. Abbott Laboratories
    • 15.3.4. Danaher Corporation
    • 15.3.5. Illumina, Inc.
    • 15.3.6. Qiagen N.V.
    • 15.3.7. Bio-Rad Laboratories, Inc.
    • 15.3.8. DiaSorin S.p.A.
    • 15.3.9. CareDx, Inc.
    • 15.3.10. Natera, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. TRANSPLANT DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. TRANSPLANT DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. TRANSPLANT DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DONOR RECIPIENT MATCHING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DONOR RECIPIENT MATCHING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DONOR RECIPIENT MATCHING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DONOR RECIPIENT MATCHING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DONOR RECIPIENT MATCHING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DONOR RECIPIENT MATCHING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GRAFT MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GRAFT MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GRAFT MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GRAFT MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GRAFT MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GRAFT MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIGH RESOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIGH RESOLUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIGH RESOLUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIGH RESOLUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIGH RESOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIGH RESOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LOW RESOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LOW RESOLUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LOW RESOLUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LOW RESOLUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LOW RESOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LOW RESOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY BACTERIAL SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY BACTERIAL SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY BACTERIAL SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY BACTERIAL SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY BACTERIAL SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY BACTERIAL SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FUNGAL SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FUNGAL SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FUNGAL SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FUNGAL SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FUNGAL SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FUNGAL SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EPSTEIN BARR VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EPSTEIN BARR VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EPSTEIN BARR VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EPSTEIN BARR VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EPSTEIN BARR VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EPSTEIN BARR VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEPATITIS VIRUSES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEPATITIS VIRUSES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEPATITIS VIRUSES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEPATITIS VIRUSES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEPATITIS VIRUSES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEPATITIS VIRUSES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HIV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ENZYMATIC ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ENZYMATIC ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ENZYMATIC ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ENZYMATIC ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ENZYMATIC ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ENZYMATIC ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY QPCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY QPCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY QPCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY QPCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY QPCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANGER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANGER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANGER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANGER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANGER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANGER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TRANSPLANT CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TRANSPLANT CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TRANSPLANT CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TRANSPLANT CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TRANSPLANT CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TRANSPLANT CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY VIRAL SCREENING, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE TRANSPLANT DIAGNOSTICS MARKET SIZE,